Much has been written regarding the long history of collaboration between the pharmaceutical industry and academia. These collaborations have led to the production, Food and Drug Administration (FDA) 2 approval, and widespread use of a myriad of pharmaceutical agents. Traditionally, industry has primarily relied upon academia for the identification of novel drug targets and subsequently to conduct clinical trials to evaluate the safety and efficacy of manufactured products. Academia and industry have differing primary motivationsdissemination vs profit-but share the common goal of advancing healthcare. In the emerging age of "openaccess" science, new models for partnership have evolved. Private-public partnerships (PPPs) and mixed consortiums are gaining strength and are examples of how "shared science" can accelerate the rate of discovery and innovation.
In a recent article in Nature (1 ), Aled Edwards, the chief executive of the Structural Genomics Consortium (SGC), discusses how combining commercial and academic incentives and resources can improve science. The SGC, an open collaborative network of scientists in hundreds of universities and 9 global pharmaceutical companies, was initiated by several drug companies that had a common need for the elucidation of human protein structures. They pooled resources with government bodies to fund the creation of the SGC. Projects have now extended beyond the determination of protein structures to the discovery and production of chemical probes, novel technologies, and shared reagents.
The article outlined 8 reinforcing factors that characterize a successful PPP. They include: (a) reward efficiency-remaining funds can be used to pursue other academic interests, (b) define objectives that cannot be achieved with current technology to stimulate innova-tion, (c) establish clear quality criteria-SGC crafted quantitative measures to judge research outputs, (d) mandate data sharing-SGC researchers utilize electronic laboratory notebooks to enhance dissemination and promote reproducibility, (e) subject work to independent oversight before public release, ( f ) enshrine public ownership for all research outputs-SGC demands unrestricted use of resulting data and reagents, (g) ensure that industry and academic scientists collaborate-industry must provide expertise in addition to funding, and (h) create an active governing body. Edwards argues that open-access PPPs allow for innovation that is less influenced by personal, institutional, or commercial gain. SGC scientists have published 800ϩ peer-reviewed papers; however, with this model, publications are no longer the only measure of productivity-achieving milestones and creating useful tools are required for continued funding.
In contrast to the abundance of literature regarding the collaboration between pharma and academia, there is very little written about industry-academia partnerships that drive the development of new laboratory diagnostics. PPPs and consortiums have been created, such as the Biomarker Consortium; however, few are designed with open access as a primary goal similar to the SGC. There still exists a gap between the discovery of a potential biomarker to the evaluation and production of FDAapproved in vitro diagnostics (IVD). As a response, the FDA has emphasized more discipline in biomarker assay development through its Critical Path Initiative. Creative approaches to open-access PPPs in IVD could be a solution to bottlenecks in the biomarker pipeline.
